CMV and DTaP vaccines
Executive Summary
The vaccines committee will discuss ways to demonstrate attenuation of chimeric strains of cytomegaloviral candidate vaccines to support proceeding into clinical trials on the morning of Nov. 4. In the afternoon, the committee will review safety data following a fifth consecutive dose of Connaught's Tripedia (diphtheria/tetanus/acellular pertussis vaccine). The meeting will be held at the Holiday Inn in Bethesda, Md., beginning at 8 a.m. each day. The committee will meet in closed session from 8-9 a.m. on Nov. 4 and from 1:30-2 p.m. on Nov. 5